

Review on Preoperative Nutritional Status in Gastric Cancer Patients

Anusha Badarla*

Department of Pharmaceutical Analysis and Quality Assurance, SLC College of Pharmacy, Telangana, India

Review Article

Received: 11/11/2016
Revised: 19/11/2016
Accepted: 29/11/2016

*For Correspondence

Anusha Badarla, Department of Pharmaceutical Analysis and Quality Assurance, SLC College of Pharmacy, Telangana, India.

Email:

anushampharm2015@gmail.com

Keywords: Gastric cancer, nutrition, malnutrition, diagnosis

ABSTRACT

Assessment of preoperative nutritional status for surgery experiencing patients really affects directly on postoperative diagnosis, general survival and illness particular survival. General complexities and hospital stay will be reduced in case of perioperative nutritional support supplemented with immune stimulating nutrients. Length of hospitalization will be reduced while the early and long-term post-operative nutritional status will be improved with early enteral nutrition after surgery. After warrant appropriate substitution and gastrectomy, common metabolic sequelae were found to be Vitamin B12 and iron deficiencies. Functional status, nutritional status, quality of life will be improved by home complimentary parenteral nourishment in-case of advances GC patients with malnutrition. Total home parenteral nourishment speaks to the main methodology of caloric admission for patients with advanced GC who can't take oral or enteral nutrition.

This review provides a summary of this proof on nutritional support in patients with GC undergoing surgery likewise as in those with advanced disorder.

INTRODUCTION

Since many decades, Gastric cancer stood at fifth place for common malignancy in the world and the third driving reason for cancer deaths in both genders overall [1-10]. GC is regularly asymptomatic, or it might bring about just nonspecific manifestations in its initial stages, which is one of the fundamental explanations behind the frequently postponed conclusion and its moderately poor diagnosis.

Weight reduction is accounted for 28-85% of patients at first analysis of cancer, and the extent of weight reduction depends specifically on the kind of tumor [11-20]. Specifically, a weight reduction >10% for the past six months is seen in 15% of patients determined to have gastroesophageal tumor, while lack of healthy sustenance happens in up to 75% of advanced GC patients [21-30].

Surveys are subjective techniques to research healthful status and techniques that equitably measure patient's status are utilized: plasma serum markers and imaging thinks about. The objective of this study is the appraisal of nourishing status of an expansive associate of gastric tumor patients utilizing target markers and the connection with the degree of the ailment [31-40].

Assessment of Nutritional values

Regular assessment of nutritional status, food intake, and severity of the disease should be made from the very first contact at short time intervals (3-6 weeks) in order to find out any nutritional loss at the earliest. Several surveys are conducted for the early detection and treatment of malnourished patients after surgery [41-50].

In a late review study on 775 patients who experienced gastrectomy for GC, the body mass record (BMI) alone did not affect perioperative grimness or repeat free or general survival [51-60]. Notwithstanding, patients with a BMI <18.5 and low preoperative albumin levels had fundamentally diminished general survival after gastrectomy. On the whole, these can be expressed as:

- Preoperative nutritious support may enhance postsurgical result in patients experiencing surgery for GC
- A few approved surveys for the early recognition and treatment of malnourished clinic patients are accessible
- The PNI, or the blend of a preoperative BMI<18.5 and low albumin levels, is prescient of diminished general survival after gastrectomy.

DISCUSSION

One of the principle reasons for our study was to check whether there are any distinctions in the clinical and natural nutritious status in patients with resectable tumors and those with unresectable or metastatic gastric tumors. In our study the patients in which resection was not reasonable introduced bring down Karnofsky files and lower Charlson comorbidities files; this was essentially brought about by the impact of the propelled tumor on body science (counting the impacts of lack of healthy sustenance) [61-70]. Those patients exhibited bring down egg whites plasmatic levels, a standout amongst the most exact instruments to explore the wholesome status. Additionally, the safe reaction was modified in those patients, they displayed bring down lymphocyte levels. The blend of egg whites and lymphocytes equation (Onodera File or Prognostic Nutritional Index) was, of course, measurably critical diverse in the two subgroups of patients. This dietary file was straightforwardly connected with more prominent tumor profundity, lymph hub metastases, lymphatic saturation and venous intrusion for gastric growth patients. Also, this record could be a novel marker of the threatening capability of human tumors [71-80]. The way that there were no distinctions of the wholesome status between those two subgroups with respect to the tumor localisation on gastric divider, could be a marker that the dietary weakness instrument in gastric disease is more intricate and it is not associated with the conceivable mechanical impact of the tumor limited in the vicinity of the cardia On the other hand the pylorus. Our study exhibits a few restrictions. We included in our concentrate every one of the patients which were alluded to our unit with a particular sign for surgery, and we barred the patients analyzed with gastric disease which were not reasonable for surgery (patients with metastatic infection or patient unfitted for surgery). The impact of those patients, with a likely hindered nutritious status could support the aftereffects of our study [81-90]. Another confinement is spoken to by the sign of surgical treatment in patients with privately propelled tumors; those patients, in light of the present suggestions, ought to have been submitted to neoadjuvant chemotherapy.

CONCLUSION

As a result, the nutritional assessment, which prompts to identification of malnourished patients or patients at danger of healthy sustenance, must be performed in each cancer patient. Dietary treatment must be started immediately after tumor diagnosis and kept amid the treatment time frame and consequently, until ailing health signs or nutritious hazard are available; this appears the best technique to lessen complexities and length of hospital stay. The effect of nutritional supplement is clinically significant to improve our quality of life, and so these nutritious evaluations must be incorporated into each anticancer strategy [91-100]. Sufficient amount of person to person nutritional necessities is warranted for identification of percentage of malnutrition.

Therefore, malnourished patients are the major risk factor in-case of postoperative morbidity and mortality while the perioperative immunonutrition positively supports the patients with malnutrition. Finally, nutritional assessment is necessary in preoperative patients.

REFERENCES

1. Hung KL. Epilepsy Comorbidity of Autism in Children. *Epilepsy*. 2016;J 2:e011.
2. Andrade-Machado R. Which are the Molecular Basis of Dysplasia Type IIIa, What Should We Know and Why?. *Epilepsy J*. 2016;2:e012.
3. de Guevara DL, et al. Can Ictal F18-FDG PET/CT Drawing Epileptogenic Zone in Refractory Focal Epilepsy? Histopathological and Outcome Correlation. *J Epilepsy*. 2016;2:109.
4. González JG, et al. A New de Novo Mutation Associated with Neurofibromatosis (NF-1). *Epilepsy J*. 2016;2:110.
5. Liao J and Xiong L. Experience of Application of Ketogenic Diet Therapy in Refractory Epilepsies. *Epilepsy J*. 2016;2:111.
6. Shaheen HA, et al. Early Atherosclerotic Changes in the Patients with Idiopathic Epilepsy: Egyptian Preliminary Study. *Epilepsy J*. 2016;2:112.
7. Alvarez-Alamilla J, et al. Conflict Processing and Response Inhibition in Patients with Temporal Lobe Epilepsy: fMRI Study. *Epilepsy J*. 2016;2:113.

8. Knežević-Pogancev M. Neonatal Seizures Characteristics and Prognosis. *Epilepsy J.* 2016;2:114.
9. Andrade-Machado R, et al. Dysplasia Type Ia, Ib and Hippocampal Sclerosis: Is Reelin the Missing Link? *Epilepsy J.* 2016;2:115.
10. Kar SK. Post-operative Delirium after Cardiac Surgery: Can it be Prevented? *J Epilepsy.* 2016;2:e107.
11. Valencia C. Calculation of the Need of Multidisciplinary Units of Epilepsy in America. *J Epilepsy.* 2016;2:e008.
12. Pilla R. The Ketogenic Diet Approach as Metabolic Treatment for a Variety of Diseases. *J Epilepsy.* 2016;2:e010.
13. Bonetti V, et al. Nav1.7 Sodium Channel Isoform is Expressed in Growth Cones of Hippocampal Neurons in Culture. *J Epilepsy.* 2016;2:106.
14. Menon D, et al. Muscle-eye-brain Disease and Drug-resistant Seizures: Unravelling the Phenotypic Heterogeneity of Congenital Muscular Dystrophies. *J Epilepsy.* 2016;2:107.
15. Andrade-Machado R. Understanding Hyper Motor Seizures. *J Epilepsy.* 2016;2:108.
16. Wang J and Carroll R. Nuclear Medicine Imaging in Epilepsy. *J Epilepsy.* 2016;2:e105.
17. Knežević-Pogancev M. Valproic Acid Induced Isolated Thrombocytopenia after Acute Respiratory Infection. *J Epilepsy.* 2016;2:e106.
18. Rolston JD. Surgical Strategies for Epilepsy in Eloquent Areas. *J Epilepsy.* 2016;2:103.
19. Sokol NJ, et al. Identical Twin Discordant for Electrical Status Epilepticus of Sleep (ESES). *J Epilepsy.* 2016;2:104.
20. Ojinnaka NC, et al. Posttraumatic Epilepsy among Epileptic Children Seen in a Pediatric Neurology Clinic in Enugu, Nigeria-A Descriptive Study. *J Epilepsy.* 2016;2:105.
21. Coleman M. Epilepsy and the Autisms. *J Ergonomics.* 2015;1:e101.
22. Guevara-Campos J. Autism, Epilepsy and Mitochondrial Disease. *J Ergonomics.* 2015;1:e102.
23. Pardo K. Neurotransmitters and Epilepsy. *J Epilepsy.* 2015;1:e103.
24. Paul R, et al. The Psychosocial Impact of Epilepsy; A Study on Adult People With Epilepsy Attending Clinics In Lusaka. *J Epilepsy.* 2015;1:101.
25. Henkin RI. What is an Olfactory Hallucination?. *J Epilepsy.* 2015;1:e104.
26. Pinzon-Ardila A, et al. Novel TSC1 Gene Mutation in a Familial Case of Tuberous Sclerosis Complex: A Case Report. *J Epilepsy.* 2015;1:102.
27. Nicolson TJ, et al. The Post-Transcriptional Regulator EIF2S3 and Gender Differences in the Dog: Implications for Drug Development, Drug Efficacy and Safety Profiles. *J Drug Metab Toxicol.* 2010;1:101.
28. Griffini P, et al. Metabolites in Safety Testing: Issues and Approaches to the Safety Evaluation of Human Metabolites in a Drug that is Extensively Metabolized. *J Drug Metab Toxicol.* 2010;1:102.
29. Nicolson TJ, et al. Sex Differences in FDA Regulated Products: Research for the Future. *J Drug Metab Toxicol.* 2010;1:103.
30. Grundmann O. The Gut Microbiome and Pre-systemic Metabolism: Current State and Evolving Research. *J Drug Metab Toxicol.* 2010;1:104.
31. Uyemura K, et al. Metabolism and Toxicity of High Doses of Cyclo (his-pro) Plus Zinc in Healthy Human Subjects. *J Drug Metab Toxicol.* 2010;1:105.
32. Essawy AE, et al. Hepatotoxicity Induced by Antifungal Drug Fluconazole in the Toads (*Bufo Regularis*). *J Drug Metab Toxicol.* 2010;1:106.
33. Wang C, et al. Application of Systems Biology in Developmental Neuronal Toxicity. *J Drug Metab Toxicol.* 2011;2:e101.
34. Rudin D, et al. Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination. *J Drug Metab Toxicol.* 2011;2:107.
35. Ebomoyi EW. Establishing Genome Sequencing Centers, the Thematic Units in the Developing Nations and the Potential Medical, Public Health and Economic Implications. *J Drug Metab Toxicol.* 2011;2:108.
36. Arroyo VS, et al. (2012) Liver and Cadmium Toxicity. *J Drug Metab Toxicol.* 2012;S5:001.
37. Khargharia S, et al. Disposition Kinetic of Amoxicillin in Healthy and Nephropathic Goats with Immunological and Residual Level in Blood and Tissues. *J Drug Metab Toxicol.* 2012;S5:003.
38. Lowry JA, et al. Lead and its Effects on Cytochromes P450. *J Drug Metab Toxicol.* 2012;S5:004.
39. Di Rocco DJ, et al. Serotonin Syndrome: Opportunity for Missed Diagnosis. *J Drug Metab Toxicol.* 2011;2:109.
40. Oezguen N and Kumar S. Analysis of Cytochrome P450 Conserved Sequence Motifs between Helices E and H: Prediction of Critical Motifs and Residues in Enzyme Functions. *J Drug Metab Toxicol.* 2011;2:110.
41. Yilmaz H and Kaya M. Acute Mixed Hepatitis Induced by Propylthiouracyl. Case Report. *J Drug Metab Toxicol.* 2011;2:111.
42. Yacob AR, et al. Detection of Vapour Metabolites of Glue Sniffer's Urine Using Head Space Gas Chromatography Mass Spectrometry. *J Drug Metab Toxicol.* 2011;2:112.
43. Kara B, et al. Hyperamylasemia After Over Purchase of Clonazepam. *J Drug Metab Toxicol.* 2011;2:113.
44. Santosh Kumar. Role of Cytochrome P450 Systems in Substance of Abuse Mediated HIV-1 Pathogenesis and NeuroAIDS. *J Drug Metab Toxicol.* 2012;3:e102.

45. Xin-Mei C, et al. New Progress on the Pharmacological and Pharmacokinetical Study of Ginsenoside Rg3. *J Drug Metabol Toxicol.* 2012;3:114.
46. Waring JF, et al. Gene Expression Changes Related to Synaptic Deficits in the Tg2576 Mouse Model of Alzheimer's Disease. *J Drug Metab Toxicol.* 2012;3:115.
47. Ansari R. Defining the Role of Single Nucleotide Polymorphic (SNP) in Drug Development and Toxicity. *J Drug Metab Toxicol.* 2012;3:e103.
48. Ansari R. Editorial. *J Drug Metab Toxicol.* 2012;3:e104.
49. Colalto C. Unpredictable Adverse Reactions to Herbal Products. *J Drug Metab Toxicol.* 2012;3:e105.
50. Johnson DE. Predicting Drug Safety: Next Generation Solutions. *J Drug Metab Toxicol.* 2012;3:e106.
51. Hou SM, et al. Susceptibility of Human Lymphocytes to 2-Nitrofluorene-Induced Gene Mutation is Strongly Dependent on Metabolic Genotypes. *J Drug Metab Toxicol.* 2012;3:e116.
52. Chen Q. Vitamin C in Cancer Treatment: Where Pharmacokinetics Speaks. *J Drug Metab Toxicol.* 2012;3:e107.
53. Yang L, et al. Sex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver. *J Drug Metab Toxicol.* 2012;3:119.
54. Sari A, et al. Determination of MDA Levels in the Plant (Some *Salvia L. Taxa* Growing in Turkey). *J Drug Metab Toxicol.* 2012;3:117.
55. Akande IS, et al. Biochemical Evaluation of Some Locally Prepared Herbal Remedies (Agbo) Currently On High Demand in Lagos Metropolis, Nigeria . *J Drug Metab Toxicol.* 2012;3:118.
56. Adebayo AJ, et al. Influence of Isoniazid Treatment on Microsomal Lipid peroxidation and Antioxidant Defense Systems of Rats. *J Drug Metab Toxicol.* 2012;3:120.
57. Nanjwade BK, et al. Development and Evaluation of Gastroretentive Floating Tablets of Glipizide Based on Effervescent Technology. *J Drug Metab Toxicol.* 2012;3:121.
58. Pathak A, et al. Role of Zinc on Antioxidative Enzymes and Lipid Peroxidation in Brain of Diabetic Rats. *J Drug Metab Toxicol.* 2012;3:122.
59. Ding WX. Autophagy in Toxicology: Defense against Xenobiotics. *J Drug Metab Toxicol.* 2012;3:e108.
60. Meier-Davis SR, et al. Absorption, Distribution and Excretion Pattern of Oral and Transdermal Donepezil Hydrochloride after Single and Repeated Administration to the Rat. *J Drug Metab Toxicol.* 2012;3:123.
61. Ozok N, Celik I. Effects of Subacute and Subchronic Treatment of Synthetic Plant Growth Regulators on Liver Damage Serum Biomarkers Tissue Antioxidant Defense Systems and Lipid Peroxidation in Rats. *J Drug Metab Toxicol.* 2012;3:124.
62. Gaies E, et al. Methotrexate Side Effects:Review Article. *J Drug Metab Toxicol.* 2012;3:125.
63. Singh JK, et al. Comparative in-vitro Intrinsic Clearance of Imipramine in Multiple Species Liver Microsomes: Human, Rat, Mouse and Dog. *J Drug Metab Toxicol.* 2012;3:126.
64. Adebayo AJ, et al. Microsomal Lipid Peroxidation, Antioxidant Enzyme Activities in Brain of Male Rats during Long-Term Exposure to Isoniazid. *J Drug Metab Toxicol.* 2012;3:127.
65. Taguchi K, et al. A Fourteen-Day Observation and Pharmacokinetic Evaluation after a Massive Intravenous Infusion of Hemoglobin-Vesicles (Artificial Oxygen Carriers) in Cynomolgus Monkeys. *J Drug Metab Toxicol.* 2012;3:128.
66. Meier-Davis SR, et al. Comparison of Metabolism of Donepezil in Rat, Mini-Pig and Human, Following Oral and Transdermal Administration, and in an in vitro Model of Human Epidermis. *J Drug Metab Toxicol.* 2012;3:129.
67. Nahata MC. Impact of Pharmacokinetics on Dosage Requirements and Medication Safety in Pediatric Patients. *J Drug Metab Toxicol.* 2012;3:e109.
68. Preissner S, et al. Drug Interactions Involving the Cytochrome P450 Enzymes:Analysis of Common Combinations of Antibiotics and Pain Relieving Drugs. *J Drug Metab Toxicol.* 2012;3:131.
69. Toffoli G. Pharmacogenetics as Innovative Approach for Phase I Clinical Studies in Cancer Patients. *J Drug Metab Toxicol.* 2012;3:e110.
70. Dwivedi VK, et al. Prevention of Cadmium Toxicity by Ceftriaxone plus Sulbactam with VPR1034 in Rats. *J Drug Metab Toxicol.* 2012;3:130.
71. Jemal A, et al. Cancer statistics 2010 CA a cancer journal for clinicians. 2010;60:277-300.
72. Correia MI and Waitzberg DL The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis. *Clin Nutr.* 2003;22:235-239.
73. Mariette C, et al. Surgery in esophageal and gastric cancer patients:what is the role for nutrition support in your daily practice? *Ann Surg Oncol.* 2012;19:2128-2134.
74. Reid BC, et al. The American Society of Anesthesiologists' class as a comorbidity index in a cohort of head and neck cancer surgical patients. *Head and neck.* 2001;23:985-994.
75. Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J Chronic Dis.* 1987;40:373-383.

76. Dewys WD, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *Am J Med.* 1980;69:491-497.
77. Farreras N, et al. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. *Clin Nutr.* 2005;24:55-65.
78. Correia M, et al. Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer. *Clin Nutr.* 2007;26:728-735.
79. Miao RL and Wu AW Towards personalized perioperative treatment for advanced gastric cancer. *World J Gastroenterol.* 2014;20:11586-11594.
80. Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med.* 2006;355:11-20.
81. Schuhmacher C, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European Organisation for Research and Treatment of Cancer randomized trial 40954. *J Clin Oncol.* 2010;28:5210-5218.
82. Nozoe T, et al. Prognostic nutritional index: A tool to predict the biological aggressiveness of gastric carcinoma. *Surgery today.* 2010;40:440-443.
83. Delmore G. Assessment of nutritional status in cancer patients: Widely neglected? *Support Care Cancer.* 1997;5:376-380.
84. Wadhwa R, et al. Modern oncological approaches to gastric adenocarcinoma. *Gastroenterol Clin North Am,* 2013;42:359-369.
85. Gupta D, et al. Malnutrition was associated with poor quality of life in colorectal cancer: A retrospective analysis. *J Clin Epidemiol.* 2006;59:704-709.
86. Ravasco P, et al. Cancer:disease and nutrition are key determinants of patients' quality of life. *Support Care Cancer.* 2004;12:246-252.
87. Deans C and Wigmore S. Systemic inflammation, cachexia and prognosis in patients with cancer. *Curr Opin Clin Nutr Metab Care.* 2005;8:265-269.
88. von Haehling S and Anker SD. Cachexia as a major underestimated and unmet medical need: Facts and numbers. *J Cachexia Sarcopenia Muscle.* 2010;1:1-5.
89. Donohoe C, et al. Cancer cachexia:mechanisms and clinical implications. *Gastroenterol Res Pract.* 2011;2011:601434.
90. Tong H, et al. The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients. *Support Care Cancer.* 2009;17:83-90.
91. Shahmoradi N, et al. Impact of nutritional status on the quality of life of advanced cancer patients in hospice home care. *Asian Pac J Cancer Prev.* 2009;10:1003-1009.
92. Van Cutsem E and Arends J. The causes and consequences of cancer-associated malnutrition. *Eur J Oncol Nurs.* 2005;9(suppl 2):S51-S63.
93. Bozzetti F, et al. ESPEN. ESPEN Guidelines on Parenteral Nutrition: Non-surgical oncology. *Clin Nutr,* 2009;28:445-454.
94. Asher V, et al. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. *Clin Transl Oncol.* 2011;13:499-503.
95. Onodera T, et al. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients (in Japanese) *Nihon Geka Gakkai Zasshi,* 1984;85:1001-1005.
96. Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med.* 2006;355:11-20.
97. Rey-Ferro M, et al. Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. *Nutrition.* 1997;13:878-881.
98. Sungurtekin H, et al. The influence of nutritional status on complications after major intraabdominal surgery. *J Am Coll Nutr.* 2004;23:227-232.
99. Bozzetti F. Nutritional support in patients with oesophageal cancer. *Support Care Cancer,* 2010;18:S41-S50.
100. Correia M, et al. Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer. *Clin Nutr.* 2007;26:728-735.